Impact of EU regulatory label changes for diclofenac in people with cardiovascular disease in four countries: Interrupted time series regression analysis

Analysis reported immediate reductions in diclofenac initiation in all countries (Denmark, England, the Netherlands, Scotland) for IHD, PAD and hyperlipidaemia, but diclofenac continued in some patients with contraindications. Extent varied between country and target population.


British Journal of Clinical Pharmacology